[go: up one dir, main page]

WO2010076737A1 - Procédé et appareil de commande d'un processus de traitement de lésion - Google Patents

Procédé et appareil de commande d'un processus de traitement de lésion Download PDF

Info

Publication number
WO2010076737A1
WO2010076737A1 PCT/IB2009/055893 IB2009055893W WO2010076737A1 WO 2010076737 A1 WO2010076737 A1 WO 2010076737A1 IB 2009055893 W IB2009055893 W IB 2009055893W WO 2010076737 A1 WO2010076737 A1 WO 2010076737A1
Authority
WO
WIPO (PCT)
Prior art keywords
level
meth
injury
hemoglobin
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/055893
Other languages
English (en)
Inventor
Payal Keswarpu
Balakrishnan Srinivasan
Srinivas Rao Kudavelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Priority to EP20090802012 priority Critical patent/EP2385803B1/fr
Priority to RU2011132110/14A priority patent/RU2529395C2/ru
Priority to JP2011544102A priority patent/JP5624993B2/ja
Priority to CN2009801533918A priority patent/CN102271609B/zh
Priority to US13/142,362 priority patent/US9149646B2/en
Publication of WO2010076737A1 publication Critical patent/WO2010076737A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00022—Sensing or detecting at the treatment site
    • A61B2017/00057—Light
    • A61B2017/00061—Light spectrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/242—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Definitions

  • the invention relates to a method and apparatus for controlling a process of injury therapy.
  • the drug therapy like capsaicin cream, acetaminophen, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are prescribed to reduce pain temporarily, but serious side effects are associated.
  • Physical therapy such as spa, massage, acupuncture and chiropractic manipulation, can help relieve pain for a short duration, but are usually expensive and require skilled personnel.
  • An object of this invention is to provide a method for controlling a process of injury therapy.
  • the invention provides a method of controlling the process of injury therapy, and the method comprises the steps of:
  • the invention also provides an apparatus for implementing the steps of the method as mentioned above.
  • Fig.l is a schematic diagram for illustrating an embodiment of the method according to the invention.
  • FIG. 2 is a schematic diagram for illustrating an apparatus according to an embodiment of the invention
  • Fig. 3 depicts an injury therapy device in accordance with an embodiment of the invention
  • Fig. 4 depicts an injury therapy device in accordance with another embodiment of the invention.
  • Fig.l is a schematic diagram for illustrating an embodiment of the method according to the invention.
  • the method of controlling the process of injury therapy comprises the following steps:
  • Light for injury therapy may be Monochromatic infrared light having a wavelength of 890nm.
  • cNOS constitutive isoform of Nitric Oxide Synthase
  • Nitric Oxide is produced from amino acid called L- Arginine by action of the enzyme Nitric Oxide synthase, and the enzyme has different isoforms.
  • cNOS is a key regulator of homeostasis (regulation of blood flow). Nitric Oxide via the beneficial cNOS pathway is decreased at the site of the injury. It is also well known that in the case of joints affected by Osteoarthritis, Nitric Oxide via the beneficial cNOS pathway is decreased.
  • Nitric Oxide released from the site of injury is a reasonable indicator for objective assessment of an injury pain.
  • a substantial pain relief is obtained by Nitric Oxide -based intervention without undesirable side effects through increasing circulation, decreasing nerve irritation, and decreasing inflammation in joints.
  • Nitric Oxide reacts with Oxy-hemoglobin to form Meth-hemoglobin at a very high rate, so, the amount of Meth-hemoglobin at the site of injury is proportional to Nitric Oxide.
  • the controlling signal indicates to increase the dosage of light (or the intensity of light), if the Nitric Oxide level is higher than the predefined threshold; the controlling signal indicates to decrease the dosage of light, if the Nitric Oxide level is lower than the predefined threshold.
  • the monitoring step 11 is intended to:
  • Nitric Oxide level calculates the Nitric Oxide level according to a proportional relationship between the Meth-hemoglobin level and the Nitric Oxide level.
  • Nitric oxide gets associated with Oxy-hemoglobin when dissolved in blood.
  • the Nitric Oxide and Oxy-hemoglobin in blood are converted to Meth-hemoglobin.
  • the most important reactions of Nitric Oxide are with ferrous Hemoproteins, and especially with Oxy- hemoglobin which yields Meth-hemoglobin:
  • Hemoglobin is the quantitatively predominant heme protein in mammals.
  • the primary function of Hemoglobin is to bind, transport, and release molecular oxygen.
  • Hemoglobin bound iron remains in the ferrous state (for example, Oxy-hemoglobin) during oxygen binding, transporting and releasing.
  • Oxy-hemoglobin Oxy-hemoglobin
  • the Oxidized Hemoglobin is called Meth-hemoglobin.
  • the Meth-hemoglobin level can be detected by: firstly, detecting a magnetic field formed due to transition from Fe 2+ to Fe 3+ , and then acquiring a Fe 3+ level according to the magnetic field, finally calculating the Meth-hemoglobin level according to the Fe 3+ level.
  • Measuring the ferric iron (Fe 3+ ) can indirectly measure the Meth-hemoglobin. Furthermore, Meth-hemoglobin is proportional to Nitric Oxide, so measuring the ferric iron will measure Nitric Oxide as an indicator of adjusting the dosage of light for injury therapy.
  • Iron is found in two principle ionic states called ferrous (Fe 2+ ) and ferric (Fe 3+ ). Magnetism occurs when there is an imbalance in the structural arrangement of the ions.
  • the ferrous ion has a charge of positive two (+2); the ferric ion has a charge of positive three (+3).
  • the two ions have different atomic radii, because the higher charge of the ferric ions pulls the electrons surrounding the ion in tighter, which can lead to electrons that move from the ferrous to the higher positively charged ferric ions, and create a slight magnetic field.
  • the proposed embodiment of the invention measures the magnetic field (also called magnetic flux density, measured in Tesla SI unit).
  • the Meth-hemoglobin level can be detected by:
  • a surface near the injury.
  • the surface may be illuminated by a specific detecting light source for detecting Meth-hemoglobin, and the specific detecting light source is different from the light source for the injury therapy.
  • the surface may be illuminated by the same light source for the injury therapy.
  • a broadband light source like the Welch Allyn refiectorized lamp assembly (part number 7103-001), may be used to illuminate the surface near an injury.
  • Oxyhemoglobin has a absorption spectra at 542nm and 580nm, whereas Meth-hemoglobin has a absorption spectra at 630nm.
  • Nitric Oxide is released from bound form to diffuse into the surrounding injury, a shift of absorption spectra from 630nm to 542/580nm occurs.
  • the reflected light from the surface may be collected by fiber-optic cables and directed towards a micro- spectrometer sensitive to light in the wavelength range (500-700nm).
  • Meth-hemoglobin level based on the ratio between the Meth-hemoglobin level and the Oxy-hemoglobin level.
  • the Meth-hemoglobin level can be detected by:
  • the surface may be illuminated by specific light source used for detection of Meth-hemoglobin, and the specific light source used for detection is different from the light source for the injury therapy.
  • the surface may also be illuminated by the same light source as that used for injury therapy.
  • the photodiodes are predefined as sensitive to three peaks 542 nm, 580 nm and 630 nm.
  • Meth-hemoglobin level based on the ratio between the Meth-hemoglobin level and the Oxy-hemoglobin level.
  • Fig. 2 is a schematic diagram for illustrating an apparatus according to an embodiment of the invention.
  • the apparatus for controlling the process of an injury therapy comprises:
  • a generating unit 22 for generating a controlling signal by comparing the Nitric Oxide level with a predefined threshold
  • - an adjusting unit 23 for adjusting a dosage of light for the injury therapy according to the controlling signal.
  • Light for injury therapy may be Monochromatic infrared light having a wavelength of 890nm. When the light is applied at a surface of an injury, the light is absorbed by the blood and stimulates production of Nitric Oxide in joints by the beneficial cNOS pathway.
  • Nitric Oxide released from an injury is a reasonable indicator for objective assessment of an injury pain.
  • a substantial pain relief is obtained by Nitric Oxide -based intervention without undesirable side effects through increasing circulation, decreasing nerve irritation, and decreasing inflammation in joints.
  • the controlling signal indicates to increase the dosage, if the Nitric Oxide level is higher than the predefined threshold; the controlling signal indicates to decrease the dosage, if the Nitric Oxide level is lower than the predefined threshold.
  • the monitoring unit 21 is intended to receive information, shown as IF in Fig. 2, and to monitor the Nitric Oxide level according to the received information.
  • the information may comprise magnetic field information, spectrum information etc.
  • the adjusting unit 23 is intended to output an adjusted dosage of light, shown as AD in Fig. 2. 5
  • the monitoring unit 21 is intended to:
  • Nitric Oxide level calculates the Nitric Oxide level according to a proportional relationship between the Meth-hemoglobin level and the Nitric Oxide level.
  • Nitric Oxide reacts with Oxy-hemoglobin to form Meth-hemoglobin at a very high rate, and so Meth-hemoglobin is proportional to Nitric Oxide.
  • Nitric oxide gets associated with Oxy-hemoglobin when dissolved in blood.
  • Nitric Oxide and Oxy-hemoglobin in blood is converted to Meth-hemoglobin.
  • the most important reactions of Nitric Oxide are with ferrous Hemoproteins, and especially with Oxyhemoglobin which yields Meth-hemoglobin:
  • Hemoglobin is the quantitatively predominant heme protein in mammals.
  • the primary function of Hemoglobin is to bind, transport, and release molecular oxygen.
  • Hemoglobin bound iron remains in the ferrous state (for example, Oxy-hemoglobin) during oxygen binding, transporting and releasing.
  • ferrous state for example, Oxy-hemoglobin
  • the Oxidized Hemoglobin is called Meth-hemoglobin.
  • the monitoring unit 21 may detect the Meth-hemoglobin level by: detecting a magnetic field formed due to transition from Fe 2+ to Fe 3+ ' and then acquiring a Fe 3+ level according to the magnetic field, finally calculating the Meth-hemoglobin level O according to the Fe + level.
  • Measuring the ferric iron (Fe + ) can indirectly measure the Meth-hemoglobin.
  • Meth-hemoglobin is proportional to Nitric Oxide, and so measuring the ferric iron will measure Nitric Oxide as an indicator of adjusting the dosage of light for injury therapy.
  • Iron is found in two principle ionic states called ferrous (Fe ) and ferric (Fe ). Magnetism occurs when there is an imbalance in the structural arrangement of the ions.
  • the ferrous ion has charge of positive two (+2); the ferric ion has a charge of positive three (+3).
  • the two ions have different atomic radii because the higher charge of the ferric ions pulls the electrons surrounding the ion in tighter, which can lead to electrons that move from the ferrous to the higher positively charged ferric ions, and create a slight magnetic field.
  • the proposed embodiment of the invention measures the magnetic field (also called magnetic flux density, measured in Tesla SI unit).
  • the monitoring unit 21 may be intended to detect the
  • Meth-hemoglobin level by:
  • the surface may be illuminated by a specific light source used for detecting Meth-hemoglobin, and the specific light source for detection is different from the light for the injury therapy.
  • the surface may also be illuminated by the same light source used for the injury therapy.
  • a broadband light source like the Welch Allyn reflectorized lamp assembly (part number 7103-001), may be used to illuminate the surface near the injury.
  • Oxy-hemoglobin has a absorption spectra at 542 and 580nm
  • Meth-hemoglobin has a absorption spectra at 630nm.
  • the light reflected from the surface may be collected by fiber-optic cables and directed towards a micro-spectrometer sensitive to light in the wavelength range (500-700nm). - analyzing a ratio between a Meth-hemoglobin level and an Oxy-hemoglobin level according to the spectrum.
  • Meth-hemoglobin level based on the ratio between the Meth- hemoglobin level and the Oxy-hemoglobin level.
  • the monitoring unit 21 may be further intended to detect the Meth-hemoglobin by:
  • the surface may be illuminated by a specific light source used for detecting Meth-hemoglobin, and the specific light source used as the detection light is different from the light for the injury therapy.
  • the surface may also be illuminated by the same light source as that used for injury therapy.
  • the photodiodes are predefined as sensitive to three peaks 542 nm, 580 nm and 630 nm.
  • a ratio between a Meth-hemoglobin level and an Oxy-hemoglobin level according to the current The Oxy-hemoglobin peaks at 542 nm and 580 nm are identified, and the intensity of Oxy-hemoglobin is compared against the Meth-hemoglobin peak at 630 nm. The ratio of the peaks are then calculated and compared against a predefined model.
  • Fig. 3 depicts an injury therapy device in accordance with an embodiment of the invention.
  • the therapy device 30 comprises a plurality of light sources 31 and the apparatus 20
  • the apparatus 20 comprises the monitoring unit 21, the generating unit 22, and the adjusting unit 23.
  • the monitoring unit 21 may also comprise a plurality of the sensors 32 arranged together with the plurality of light sources 31.
  • the light source 31 may be LEDs (Light Emitting Diode) for emitting light on an injury for therapy.
  • the monitoring unit 21 is used to monitor the Nitric Oxide level of the injury, so as to adjust dosage of light.
  • the adjusting unit 23 is intended to adjust the dosage of the light for therapy by adjusting the total intensity of the light, e.g. turning off/on one or more light source, adjusting intensities of one or more lights, or adjusting the intensities of all lights.
  • the sensors 32 are used for collecting information of an injury for the monitoring unit 21.
  • the light sources 31 and the sensors 32 are placed on a base (not labeled).
  • the base is flexible to adjust to any part of body.
  • the injury therapy device 30 can be used by patient at home or work and does not need expert intervention.
  • the apparatus 20 may be supported by one or more CPUs (Central Processing Units) and/or control circuits, so as to adjust the dosage of the lights emitted from the light sources 31.
  • the light sources 31 are powered by battery source or other elements.
  • FIG. 4 depicts an injury therapy device in accordance with another embodiment of the invention.
  • (A) depicts the composition of the LED and GMR sensors in the device;
  • (B) depicts measuring magnetic field by each GMR sensor;
  • (C) depicts a combination of the magnetic fields from all the GMR sensors.
  • the therapy device 30 comprises a plurality of light sources 31 and the apparatus 20 (not shown in Fig. 3).
  • the apparatus 20 comprises the monitoring unit 21, the generating unit 22, and the adjusting unit 23.
  • the monitoring unit 21 may also comprise a plurality of the sensors 32 arranged together with the plurality of light sources 31.
  • the sensors 32 are Giant Magneto Resistive (GMR) sensors for detecting the magnetic field.
  • the GMR sensors are more sensitive than the Hall-effect sensors.
  • the sensors 32 consist of three by three arrays.
  • An analog multiplexer (not shown in Fig. 4) may be used to select the signals from the nine sensors 32 for further signal conditioning, amplification, and analog to digital conversion.
  • the light sources 31 can emit lights in the infrared range approximately around
  • the apparatus 20 computes an initial magnetic field (B 1n ); when the therapy starts, the apparatus 20 periodically computes the magnetic field (B cur ), and the B cur is higher than the B 1n , so as to monitor the Nitric Oxide level.
  • Bcur ⁇ B 1 ; wherein i is equal to 1 to n, i represents the number of GMR

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Radiation-Therapy Devices (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

L'invention porte sur un procédé et un appareil de commande d'un processus de traitement de lésion. Le procédé comprend les étapes consistant à : - surveiller (11) le taux d'oxyde nitrique de la plaie ; - générer (12) un signal de commande par comparaison du taux d'oxyde nitrique avec un seuil prédéfini, et - ajuster (13) une quantité de lumière pour le traitement de plaie selon le signal de commande.
PCT/IB2009/055893 2008-12-31 2009-12-22 Procédé et appareil de commande d'un processus de traitement de lésion Ceased WO2010076737A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20090802012 EP2385803B1 (fr) 2008-12-31 2009-12-22 Appareil de commande d'un traitement lumineux de lésion
RU2011132110/14A RU2529395C2 (ru) 2008-12-31 2009-12-22 Способ и устройство для контроля над процессом лечения повреждения
JP2011544102A JP5624993B2 (ja) 2008-12-31 2009-12-22 傷害治療の処置を制御するための方法及び装置
CN2009801533918A CN102271609B (zh) 2008-12-31 2009-12-22 用于控制损伤的治疗过程的装置
US13/142,362 US9149646B2 (en) 2008-12-31 2009-12-22 Method and apparatus for controlling a process of injury therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810190333 2008-12-31
CN200810190333.X 2008-12-31

Publications (1)

Publication Number Publication Date
WO2010076737A1 true WO2010076737A1 (fr) 2010-07-08

Family

ID=41819675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/055893 Ceased WO2010076737A1 (fr) 2008-12-31 2009-12-22 Procédé et appareil de commande d'un processus de traitement de lésion

Country Status (6)

Country Link
US (1) US9149646B2 (fr)
EP (1) EP2385803B1 (fr)
JP (1) JP5624993B2 (fr)
CN (1) CN102271609B (fr)
RU (1) RU2529395C2 (fr)
WO (1) WO2010076737A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629358B2 (en) * 2013-03-15 2017-04-25 Mallinckrodt Hospital Products IP Limited Administration and monitoring of nitric oxide in ex vivo fluids
US10952682B2 (en) 2015-07-19 2021-03-23 Sanmina Corporation System and method of a biosensor for detection of health parameters
US9642538B2 (en) * 2015-07-19 2017-05-09 Sanmina Corporation System and method for a biosensor monitoring and tracking band
US10973470B2 (en) * 2015-07-19 2021-04-13 Sanmina Corporation System and method for screening and prediction of severity of infection
US10194871B2 (en) 2015-09-25 2019-02-05 Sanmina Corporation Vehicular health monitoring system and method
US10321860B2 (en) 2015-07-19 2019-06-18 Sanmina Corporation System and method for glucose monitoring
US9788767B1 (en) 2015-09-25 2017-10-17 Sanmina Corporation System and method for monitoring nitric oxide levels using a non-invasive, multi-band biosensor
US10744261B2 (en) 2015-09-25 2020-08-18 Sanmina Corporation System and method of a biosensor for detection of vasodilation
US10736580B2 (en) 2016-09-24 2020-08-11 Sanmina Corporation System and method of a biosensor for detection of microvascular responses
US10932727B2 (en) 2015-09-25 2021-03-02 Sanmina Corporation System and method for health monitoring including a user device and biosensor
US10888280B2 (en) 2016-09-24 2021-01-12 Sanmina Corporation System and method for obtaining health data using a neural network
US10750981B2 (en) 2015-09-25 2020-08-25 Sanmina Corporation System and method for health monitoring including a remote device
US9636457B2 (en) 2015-07-19 2017-05-02 Sanmina Corporation System and method for a drug delivery and biosensor patch
US9968289B2 (en) * 2015-09-25 2018-05-15 Sanmina Corporation System and method for detecting a sepsis condition
US10945676B2 (en) 2015-09-25 2021-03-16 Sanmina Corporation System and method for blood typing using PPG technology
US10466783B2 (en) 2018-03-15 2019-11-05 Sanmina Corporation System and method for motion detection using a PPG sensor
WO2022133258A1 (fr) * 2020-12-18 2022-06-23 The Johns Hopkins University Prédiction en temps réel de résultats défavorables à l'aide d'un apprentissage automatique
WO2025237757A1 (fr) * 2024-05-14 2025-11-20 Koninklijke Philips N.V. Système d'évaluation de la santé tissulaire

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139348A (en) * 1975-11-28 1979-02-13 Massachusetts Institute Of Technology Electrochemical process and apparatus to control the chemical state of a material
WO2001074252A2 (fr) * 2000-03-31 2001-10-11 Rita Medical Systems Inc. Biopsie des tissus, appareil et procede de traitement
US20040111016A1 (en) * 1996-09-20 2004-06-10 Texas Heart Institute Method and apparatus for detection of vulnerable atherosclerotic plaque
US20060074282A1 (en) * 2000-07-13 2006-04-06 Ward Kevin R Nitric-oxide detection using Raman spectroscopy
WO2007144810A1 (fr) * 2006-06-12 2007-12-21 Koninklijke Philips Electronics N.V. Dispositif de surveillance du corps, méthode d'acquisition de données corporelles et méthode de détermination de la présence, de l'emplacement et/ou de l'état d'une blessure
WO2008137737A2 (fr) * 2007-05-02 2008-11-13 University Of Rochester Procédé commandé par rétroaction pour traitement photodynamique et instrumentation associée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080154257A1 (en) * 2006-12-22 2008-06-26 Shiva Sharareh Real-time optoacoustic monitoring with electophysiologic catheters
US6830934B1 (en) * 1999-06-15 2004-12-14 Lifescan, Inc. Microdroplet dispensing for a medical diagnostic device
JP4376404B2 (ja) * 2000-02-01 2009-12-02 独立行政法人科学技術振興機構 生体用光照射装置
US7090648B2 (en) 2000-09-28 2006-08-15 Non-Invasive Monitoring Systems, Inc. External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention
WO2003002186A2 (fr) 2001-06-26 2003-01-09 Photomed Technologies, Inc. Methodes therapeutiques faisant appel a un rayonnement electromagnetique
EP1525003A1 (fr) * 2002-06-28 2005-04-27 Pharmacia Corporation Agents de contraste des plus utiles pour quantifier de l'oxyde nitrique et methodes a cet effet
US20040254419A1 (en) 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
WO2007047892A1 (fr) 2005-10-20 2007-04-26 Light Sciences Oncology, Inc. Systèmes portables externes de traitement de luminothérapie
JP2010526645A (ja) * 2007-05-11 2010-08-05 クラリメディックス・インコーポレイテッド 低酸素および疾病におけるミトコンドリア機能の可視光調節

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139348A (en) * 1975-11-28 1979-02-13 Massachusetts Institute Of Technology Electrochemical process and apparatus to control the chemical state of a material
US20040111016A1 (en) * 1996-09-20 2004-06-10 Texas Heart Institute Method and apparatus for detection of vulnerable atherosclerotic plaque
WO2001074252A2 (fr) * 2000-03-31 2001-10-11 Rita Medical Systems Inc. Biopsie des tissus, appareil et procede de traitement
US20060074282A1 (en) * 2000-07-13 2006-04-06 Ward Kevin R Nitric-oxide detection using Raman spectroscopy
WO2007144810A1 (fr) * 2006-06-12 2007-12-21 Koninklijke Philips Electronics N.V. Dispositif de surveillance du corps, méthode d'acquisition de données corporelles et méthode de détermination de la présence, de l'emplacement et/ou de l'état d'une blessure
WO2008137737A2 (fr) * 2007-05-02 2008-11-13 University Of Rochester Procédé commandé par rétroaction pour traitement photodynamique et instrumentation associée

Also Published As

Publication number Publication date
CN102271609A (zh) 2011-12-07
EP2385803B1 (fr) 2013-08-21
JP2012513857A (ja) 2012-06-21
US9149646B2 (en) 2015-10-06
RU2529395C2 (ru) 2014-09-27
JP5624993B2 (ja) 2014-11-12
RU2011132110A (ru) 2013-02-10
US20120010683A1 (en) 2012-01-12
CN102271609B (zh) 2013-10-30
EP2385803A1 (fr) 2011-11-16

Similar Documents

Publication Publication Date Title
EP2385803B1 (fr) Appareil de commande d'un traitement lumineux de lésion
Simpson et al. Capturing step counts at slow walking speeds in older adults: comparison of ankle and waist placement of measuring device.
JP5010587B2 (ja) 組織治療装置
AU749033B2 (en) Apparatus and method for noninvasive glucose measurement
ATE497722T1 (de) Vorrichtung und verfahren zur überwachung von körperflüssigkeit und elektrolytenstörungen
WO2015051013A9 (fr) Système portable et procédé pour mesurer et surveiller des rayonnements de lumières ultraviolette, visible, et infrarouge afin de fournir des recommandations médicales personnalisées, d'empêcher les maladies, et d'améliorer la gestion thérapeutique
CA2220949A1 (fr) Fixation repetee destinee a une procedure stereotaxique sans cadre
EP3823525A1 (fr) Mesure de perfusion et d'oxygénation
US20140330097A1 (en) Method and system for a non-invasive measurement of optically active component concentration
JP2020146486A (ja) 皮膚状態検知装置
KR20180059984A (ko) 일체형 마취심도 및 뇌산소포화도 감지센서
Molina et al. Serum lipid peroxides in patients with Parkinson's disease
Sainsbury Critical evaluation of the clinimetrics of laser Doppler imaging in burn assessment
CN106073718A (zh) 定量检测5‑ALA诱导的PpIX浓度分布的荧光相机及荧光定量方法
JPH06254170A (ja) レーザ治療装置用プローブ
US11350872B1 (en) Footsmart mat
Manwaring et al. Correlation of cerebral oximetry with internal carotid artery stump pressures in carotid endarterectomy
US20110178408A1 (en) Accurate Low-Cost Non-Invasive Body Fat Measurement
CN209661662U (zh) 可检测脑深部核团血氧水平的脑深部刺激电极
BR0317404A (pt) Variantes do fator xiia
Raizman Prospective clinical evaluation of fluorescence imaging in positively predicting the presence of Pseudomonas aeruginosa in chronic wounds
WO2020139830A3 (fr) Traitement de troubles respiratoires à l'aide d'inhibiteurs de l'arachidonate 15-lipoxygénase
JP2016041095A (ja) 連続血液成分測定装置
TWM384315U (en) Non-invasive optical blood sugar testing machine
FR2530450A1 (fr) Systeme de diagnostic medical

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980153391.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09802012

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2011544102

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009802012

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5404/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011132110

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13142362

Country of ref document: US